7Bymaster FP,Lee TC,KnadlerMP. The dual transporter inhibitor duloxetine:areview of its preclinical pharmacology,pharmacokinetic profile,and clinical results in depression[J].{H}Current Pharmaceutical Design,2005.1475-1493.
8Brannan SK, Mallinckrodt CH, Brown EB, et al. Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder[J].J Psych Res, 2005,39:43-53.
9Bymaster FP.Lee TC, Knadler MP, et al. The dualtransporter inhibitor duloxetine: a review of its preclinical pharmacology, pharmacokinetic profile, and clinical results in depression [J].Curr Pharm Des. 2005,11:1475-93.
10Hudson JI, Wonlreich MM, Kajdgsz DK, et al. Safety and tolerability of duloxetine in the treat ment of major depressive disorder: analysis of pooled data from eight placebo-controlled clinical trials [J]. Hum Psychopharmacol. 2005, 20 (5): 327-41.
1Yuen E, Gueorguieva I, Bueno-Burgos L, et al. Population pharmaeoki- netic/pharmacodynamic models for duloxetine in the treatment of diabet- ic peripheral neuropathic pain[ J]. Eur J Pain,2013,17 (3) :382 - 393.
2Boyle J, Eriksson ME, Gribble L, et al. Randomized, placebo-controlled comparison of amitriptyline, duloxetine, and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysom- nographic sleep, daytime functioning, and quality of life [ J ]. Diabetes Care,2012,35 (12) :2451 - 2458.
3Bennett MI, Simpson KH. Gabapentin in the treatment of neuropathic pain[ J]. PaUiat Med ,20(0,18( 1 ) :5 - 11.
